Abstract:Artificial intelligence (AI) consists of a synergistic assembly of enhanced optimization strategies with wide application in drug discovery and development, providing advanced tools for promoting cost-effectiveness throughout drug life cycle. Specifically, AI brings together the potential to improve drug approval rates, reduce development costs, get medications to patients faster, and help patients complying with their treatments. Accelerated pharmaceutical development and drug product approval rates can further benefit from the quantum computing (QC) technology, which will ultimately enable larger profits from patent-protected market exclusivity.Key pharma stakeholders are endorsing cutting-edge technologies based on AI and QC , covering drug discovery, preclinical and clinical development, and postapproval activities. Indeed, AI-QC applications are expected to become standard in the pharma operating model over the next 5-10 years. Generalizing scalability to larger pharmaceutical problems instead of specialization is now the main principle for transforming pharmaceutical tasks on multiple fronts, for which systematic and cost-effective solutions have benefited in areas such as molecular screening, synthetic pathway design, and drug discovery and development.The information generated by coupling the life cycle of drugs and AI and/or QC through data-driven analysis, neural network prediction, and chemical system monitoring will enable (1) better understanding of the complexity of process data, (2) streamlining the design of experiments, (3) discovering new molecular targets and materials, and also (4) planning or rethinking upcoming pharmaceutical challenges The power of AI-QC makes accessible a range of different pharmaceutical problems and their rationalization that have not been previously addressed due to a lack of appropriate analytical tools, demonstrating the breadth of potential applications of these emerging multidimensional approaches. In this context, creating the right AI-QC strategy often involves a steep learning path, especially given the embryonic stage of the industry development and the relative lack of case studies documenting success. As such, a comprehensive knowledge of the underlying pillars is imperative to extend the landscape of applications across the drug life cycle.The topics enclosed in this chapter will focus on AI-QC methods applied to drug discovery and development, with emphasis on the most recent advances in this field.

Data science tools and applications on the way to Pharma 4.0

Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future

Leading a Digital Transformation in the Pharmaceutical Industry: Reimagining the Way We Work in Global Drug Development

Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications

Industry 4.0 Technologies Adoption for Digital Transition in Drug Discovery and Development: A Review

Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review

The future of Artificial Intelligence for the BioTech Big Data landscape

Integration of personalized drug delivery systems into digital health

A comprehensive study on Industry 4.0 in the pharmaceutical industry for sustainable development

Developing Deep Learning Applications for Life Science and Pharma Industry

Data-Driven Modeling Methods and Techniques for Pharmaceutical Processes

Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains

Learnings from Industry 4.0 for transitioning towards Industry 4.0+: challenges and solutions for Indian pharmaceutical sector

Improving protein therapeutic development through cloud-based data integration

Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world

Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges

Digitalization in Processes

Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors

Translational precision medicine: an industry perspective

Towards a potential paradigm shift in health data collection and analysis

Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals